These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31148411)

  • 1. Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.
    Okonko DO; Jouhra F; Abu-Own H; Filippatos G; Colet JC; Suki C; Mori C; Ponikowski P; Anker SD;
    ESC Heart Fail; 2019 Aug; 6(4):621-628. PubMed ID: 31148411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
    Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
    Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
    Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
    Hofmarcher T; Borg S
    J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
    Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
    Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
    ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
    Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
    Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
    Gutzwiller FS; Schwenkglenks M; Blank PR; Braunhofer PG; Mori C; Szucs TD; Ponikowski P; Anker SD
    Eur J Heart Fail; 2012 Jul; 14(7):782-90. PubMed ID: 22689292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
    Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD
    Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
    Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
    ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
    Trenkwalder C; Winkelmann J; Oertel W; Virgin G; Roubert B; Mezzacasa A;
    Mov Disord; 2017 Oct; 32(10):1478-1482. PubMed ID: 28643901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
    Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron substitution in the treatment of chronic heart failure.
    Gstrein C; Meyer M; Anabitarte P
    Swiss Med Wkly; 2017; 147():w14453. PubMed ID: 28695549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.